Inpatient Prandial Insulin Management
Anne L. Peters, MD, CDE: Hi. I'm Dr. Anne Peters of the University of Southern California. I am speaking to you from the American Diabetes Association annual meetings in Chicago, Illinois. I am joined by Dr. Kathleen Dungan, Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at Ohio State University.
Your abstracts are in the field of inpatient diabetes management. Could you tell us what you found?
Kathleen M. Dungan, MD: For the past 5 years, our research has been in this area. The first study[1] that we are reporting is on the use of prandial insulin in hospitals. We did a randomized controlled trial comparing fixed meal dosing with carbohydrate counting in hospitals, and although ultimately we feel that the study was underpowered, we didn't find a difference in glycemic control, with the caveat that all of the dosing was done by the inpatient diabetes team.
Dr. Peters: In your model, who did the carbohydrate counting and how did they determine the doses?
Dr. Dungan: All of our meal trays for the past 6 years have come with a meal ticket that tells exactly how many carbohydrates are in each food item.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: Type 2 Diabetes in the Hospital: Improving Glucose Management - Medscape - Jun 28, 2013.
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
Type 2 Diabetes in the Hospital: Improving Glucose Management
Anne L. Peters, MD, CDE; Kathleen M. Dungan, MD
DisclosuresJune 28, 2013
Inpatient Prandial Insulin Management
Anne L. Peters, MD, CDE: Hi. I'm Dr. Anne Peters of the University of Southern California. I am speaking to you from the American Diabetes Association annual meetings in Chicago, Illinois. I am joined by Dr. Kathleen Dungan, Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at Ohio State University.
Your abstracts are in the field of inpatient diabetes management. Could you tell us what you found?
Kathleen M. Dungan, MD: For the past 5 years, our research has been in this area. The first study[1] that we are reporting is on the use of prandial insulin in hospitals. We did a randomized controlled trial comparing fixed meal dosing with carbohydrate counting in hospitals, and although ultimately we feel that the study was underpowered, we didn't find a difference in glycemic control, with the caveat that all of the dosing was done by the inpatient diabetes team.
Dr. Peters: In your model, who did the carbohydrate counting and how did they determine the doses?
Dr. Dungan: All of our meal trays for the past 6 years have come with a meal ticket that tells exactly how many carbohydrates are in each food item.
Medscape Diabetes © 2013 WebMD, LLC
Cite this: Type 2 Diabetes in the Hospital: Improving Glucose Management - Medscape - Jun 28, 2013.
Tables
References
Authors and Disclosures
Authors and Disclosures
Interviewer
Anne L. Peters, MD, CDE
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, CDE, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk.
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis
Interviewee
Kathleen M. Dungan, MD
Assistant Professor, The Ohio State University; Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Ohio State University Wexner Medical Center, Columbus, Ohio
Disclosure: Kathleen M. Dungan, MD, has disclosed the following relevant financial relationships:
Serve(d) as director, officer, partner, employee, advisor, consultant, or trustee for: Eli Lilly and Company; sanofi-aventis; Diabetes Technology Management; LipoScience Inc.
Serve(d) as a speaker or a member of a speaker bureau for: Medikinetics
Received research grant from: Novo Nordisk